ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Phase 1/2
15
about 5.5 years
1–21
2 sites in CA, MA
What this study is about
This trial is testing a treatment called ET140203 T cells in children with certain types of liver cancer. The goal is to see if the treatment is safe and determine the best dose for further testing.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ET140203 T Cells
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence rates of adverse events (AEs) after infusion of ET140203 T cells, Severity rates of adverse events (AEs) after infusion of ET140203 T cells, The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT
Secondary: Determine the pharmacokinetics of ET140203 T cells after infusion.
Oncology, Gastroenterology